<DOC>
	<DOCNO>NCT01542255</DOCNO>
	<brief_summary>SUMMARY : Metronomic Therapy Patients Metastatic Melanoma : A Phase II Study Low Dose Vinblastine , Cyclophosphamide , Dacarbazine . Patients measurable metastatic melanoma eligible . All patient treat outlined combined vinblastine , cyclophosphamide , dacarbazine . Patients treat continuously , evidence progression disease , two cycle follow disappearance disease . A cycle define three week continuous therapy one week rest .</brief_summary>
	<brief_title>Metronomic Therapy Patients With Metastatic Melanoma</brief_title>
	<detailed_description>Low dose continuous chemotherapy , call metronomic chemotherapy , design target vascular cell inhibit tumor growth metastasis . A recent study melanoma mouse model identify low dose vinblastine , cyclophosphamide dacarbazine treatment improve animal 's survival superior full dose dacarbazine alone . This clinical trial seek translate laboratory model directly metastatic melanoma patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Metastatic melanoma measurable disease Patients must least 4 week last immunotherapy , radiation , surgery chemotherapy ( 6 week nitrosoureas ) recover ill Karnofsky Performance Status ≥60 % Life expectancy ≥ twelve week Adequate end organ function Women lactating , childbearing age , negative pregnancy test within two week entry study . Appropriate Contraception sex The patient must competent sign informed consent . EXCLUSION CRITERIA Concomitant second malignancy except nonmelanoma skin cancer , noninvasive cancer cervical CIS , superficial bladder cancer without local recurrence , breast CIS . In patient prior history invasive malignancy , less five year complete remission . Have evidence significant comorbid illness uncontrolled diabetes Uncontrolled brain metastasis : Patients brain metastasis treat brain radiation therapy surgery remain clinically stable minimum 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Metronomic Therapy</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Vinblastine</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Dacarbazine</keyword>
</DOC>